Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Metastatic cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 134 for your search:
Start Over
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients with Localized Spine Metastasis
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0631, NCI-2009-01687, CDR0000646803, NCT00922974
Stereotactic Radiosurgery Compared to Observation in Treating Patients with Brain Metastases
Phase: Phase III
Type: Treatment
Age: 3 and over
Trial IDs: 2009-0381, NCI-2011-00542, NCT00950001
Hypofractionated or Single Dose Image-Guided Radiation Therapy in Treating Patients with Metastatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 10-154, NCI-2010-02150, NCT01223248
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 20090482, NCI-2013-00401, NCT01345019
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-102, NCI-2012-00575, NCT01483027
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients with Newly Diagnosed Non-melanoma Brain Metastases
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0884, NCI-2014-02058, NCI-2012-00850, NCT01592968
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Single-Fraction or Hypofractionated Stereotactic Radiosurgery in Treating Patients with Spinal Metastases
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 14-233, NCI-2014-02624, NCT02320825
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCRI CNS 13, NCI-2015-00813, NCT01349660
Imiquimod, Cyclophosphamide, and Radiation Therapy in Treating Patients with Breast Cancer with Skin Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NYU 11-00598, NCI-2011-02879, NCT01421017
Hydroxychloroquine and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT11PLK01, NCI-2012-00427, 11-080, 1302010628, NCT01550367
Rituximab in Treating Patients with Relapsed or Refractory Lymphoid Malignancies Involving the Central Nervous System
Phase: Phase II, Phase I
Type: Treatment
Age: 3 and over
Trial IDs: 2011-0844, NCI-2012-00849, NCT01596127
Stereotactic Radiosurgery in Treating Patients with Large Brain Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 8312, NCI-2013-00845, CASE8312, NCT01843413
Radiosurgery Before Surgery in Treating Patients with Brain Metastases That Can be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 7312, NCI-2013-00644, NCT01891318
Genetically Engineered Lymphocytes and Aldesleukin after Cyclophosphamide and Fludarabine Phosphate in Treating Patients with Metastatic or Locally Advanced Refractory/Recurrent Cancer That Expresses MAGE-A3
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0110, NCI-2014-02496, 140110, 1402-1293, 338101, P131467, RD-14-III-03, NCT02153905
Ipilimumab and Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients with Advanced Solid Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0882, NCI-2015-00042, NCT02239900
Stereotactic Body Radiation Therapy in Treating Patients with Painful Bone Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STAT-RT-1/2, NCI-2014-00968, 16964, STAT RAD 2, NCT02145286
Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Pain in Patients with Localized Spinal Metastasis
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: STU 072010-134, NCI-2015-01674, SCCC-112008-022, 112008-022, SBRT Spine, NCT00855803
Stereotactic Body Radiation Therapy, Radiofrequency Ablation, and Microwave Ablation in Treating Patients with Inoperable and Recurrent Lung Cancer Near Central Airways
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-08-026, NCI-2010-01669, 10-000656, JCCC-SUPPL-3, NCT01051037
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Panitumumab in Treating Patients with Locally Advanced or Metastatic Small Intestine or Ampulla of Vater Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2009-0458, NCI-2012-01894, NCI-2010-02085, NCT01202409
Retaspimycin Hydrochloride in Treating Patients With Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-134, NCI-2010-01918, NCT01119495, NCT01228435
Start Over